nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—PTGS2—malignant glioma	0.381	1	CbGaD
Etoricoxib—CYP1A2—Carmustine—malignant glioma	0.149	0.569	CbGbCtD
Etoricoxib—CYP3A4—Temozolomide—malignant glioma	0.113	0.43	CbGbCtD
Etoricoxib—Alveolitis—Temozolomide—malignant glioma	0.0107	0.0806	CcSEcCtD
Etoricoxib—Vemurafenib—RAF1—malignant glioma	0.00603	0.561	CrCbGaD
Etoricoxib—Nephrotoxicity—Carmustine—malignant glioma	0.00438	0.0329	CcSEcCtD
Etoricoxib—Vemurafenib—BRAF—malignant glioma	0.00418	0.389	CrCbGaD
Etoricoxib—MAPK14—blood vessel—malignant glioma	0.00288	0.159	CbGeAlD
Etoricoxib—Transient ischaemic attack—Temozolomide—malignant glioma	0.00267	0.02	CcSEcCtD
Etoricoxib—Nephropathy toxic—Carmustine—malignant glioma	0.00243	0.0182	CcSEcCtD
Etoricoxib—Haemorrhoids—Temozolomide—malignant glioma	0.00229	0.0172	CcSEcCtD
Etoricoxib—Cyst—Carmustine—malignant glioma	0.00209	0.0156	CcSEcCtD
Etoricoxib—Vaginal haemorrhage—Temozolomide—malignant glioma	0.00182	0.0136	CcSEcCtD
Etoricoxib—Hepatotoxicity—Carmustine—malignant glioma	0.00181	0.0135	CcSEcCtD
Etoricoxib—Herpes zoster—Temozolomide—malignant glioma	0.00179	0.0134	CcSEcCtD
Etoricoxib—Hepatotoxicity—Temozolomide—malignant glioma	0.00174	0.0131	CcSEcCtD
Etoricoxib—Memory impairment—Temozolomide—malignant glioma	0.00172	0.0129	CcSEcCtD
Etoricoxib—MAPK14—embryo—malignant glioma	0.00172	0.0947	CbGeAlD
Etoricoxib—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.00164	0.0123	CcSEcCtD
Etoricoxib—MAPK14—brainstem—malignant glioma	0.00157	0.0868	CbGeAlD
Etoricoxib—Herpes simplex—Temozolomide—malignant glioma	0.00146	0.011	CcSEcCtD
Etoricoxib—Neck pain—Carmustine—malignant glioma	0.00141	0.0106	CcSEcCtD
Etoricoxib—MAPK14—telencephalon—malignant glioma	0.0014	0.077	CbGeAlD
Etoricoxib—Musculoskeletal pain—Temozolomide—malignant glioma	0.00136	0.0102	CcSEcCtD
Etoricoxib—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.00135	0.0101	CcSEcCtD
Etoricoxib—Neuropathy—Carmustine—malignant glioma	0.00131	0.00981	CcSEcCtD
Etoricoxib—Vaginal infection—Temozolomide—malignant glioma	0.00127	0.00954	CcSEcCtD
Etoricoxib—Neuropathy—Temozolomide—malignant glioma	0.00127	0.00948	CcSEcCtD
Etoricoxib—Neoplasm—Carmustine—malignant glioma	0.00126	0.00945	CcSEcCtD
Etoricoxib—Neoplasm—Temozolomide—malignant glioma	0.00122	0.00913	CcSEcCtD
Etoricoxib—Diabetes mellitus—Carmustine—malignant glioma	0.00116	0.00872	CcSEcCtD
Etoricoxib—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.00112	0.00843	CcSEcCtD
Etoricoxib—Gastroenteritis—Temozolomide—malignant glioma	0.0011	0.00827	CcSEcCtD
Etoricoxib—Injury—Carmustine—malignant glioma	0.0011	0.00826	CcSEcCtD
Etoricoxib—Hepatic failure—Temozolomide—malignant glioma	0.00109	0.00816	CcSEcCtD
Etoricoxib—Thirst—Temozolomide—malignant glioma	0.00103	0.00771	CcSEcCtD
Etoricoxib—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.00101	0.00759	CcSEcCtD
Etoricoxib—MAPK14—spinal cord—malignant glioma	0.000978	0.054	CbGeAlD
Etoricoxib—PTGS2—endothelium—malignant glioma	0.000897	0.0495	CbGeAlD
Etoricoxib—Muscular weakness—Carmustine—malignant glioma	0.000893	0.00669	CcSEcCtD
Etoricoxib—Breast disorder—Temozolomide—malignant glioma	0.000884	0.00663	CcSEcCtD
Etoricoxib—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000881	0.0066	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000881	0.0066	CcSEcCtD
Etoricoxib—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000863	0.00647	CcSEcCtD
Etoricoxib—Muscular weakness—Temozolomide—malignant glioma	0.000863	0.00647	CcSEcCtD
Etoricoxib—Abdominal distension—Temozolomide—malignant glioma	0.000851	0.00638	CcSEcCtD
Etoricoxib—PTGS2—blood vessel—malignant glioma	0.000827	0.0456	CbGeAlD
Etoricoxib—Bronchitis—Temozolomide—malignant glioma	0.000813	0.0061	CcSEcCtD
Etoricoxib—MAPK14—central nervous system—malignant glioma	0.000793	0.0438	CbGeAlD
Etoricoxib—Hyperglycaemia—Carmustine—malignant glioma	0.000789	0.00592	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000786	0.00589	CcSEcCtD
Etoricoxib—Pneumonia—Carmustine—malignant glioma	0.000784	0.00588	CcSEcCtD
Etoricoxib—MAPK14—cerebellum—malignant glioma	0.000775	0.0428	CbGeAlD
Etoricoxib—Photosensitivity reaction—Temozolomide—malignant glioma	0.000772	0.00579	CcSEcCtD
Etoricoxib—Weight increased—Temozolomide—malignant glioma	0.000769	0.00577	CcSEcCtD
Etoricoxib—Renal failure—Carmustine—malignant glioma	0.000767	0.00575	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Carmustine—malignant glioma	0.000765	0.00573	CcSEcCtD
Etoricoxib—Hyperglycaemia—Temozolomide—malignant glioma	0.000763	0.00572	CcSEcCtD
Etoricoxib—Stomatitis—Carmustine—malignant glioma	0.00076	0.0057	CcSEcCtD
Etoricoxib—Urinary tract infection—Carmustine—malignant glioma	0.000758	0.00568	CcSEcCtD
Etoricoxib—Pneumonia—Temozolomide—malignant glioma	0.000758	0.00568	CcSEcCtD
Etoricoxib—Infestation NOS—Temozolomide—malignant glioma	0.000754	0.00565	CcSEcCtD
Etoricoxib—Infestation—Temozolomide—malignant glioma	0.000754	0.00565	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000747	0.0056	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Temozolomide—malignant glioma	0.000739	0.00554	CcSEcCtD
Etoricoxib—Stomatitis—Temozolomide—malignant glioma	0.000735	0.00551	CcSEcCtD
Etoricoxib—Urinary tract infection—Temozolomide—malignant glioma	0.000733	0.00549	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Temozolomide—malignant glioma	0.000713	0.00534	CcSEcCtD
Etoricoxib—Sinusitis—Temozolomide—malignant glioma	0.000707	0.0053	CcSEcCtD
Etoricoxib—Haemoglobin—Carmustine—malignant glioma	0.000704	0.00528	CcSEcCtD
Etoricoxib—Haemorrhage—Carmustine—malignant glioma	0.0007	0.00525	CcSEcCtD
Etoricoxib—Hypoaesthesia—Carmustine—malignant glioma	0.000697	0.00522	CcSEcCtD
Etoricoxib—Hallucination—Carmustine—malignant glioma	0.000697	0.00522	CcSEcCtD
Etoricoxib—Oedema peripheral—Carmustine—malignant glioma	0.00069	0.00517	CcSEcCtD
Etoricoxib—Connective tissue disorder—Carmustine—malignant glioma	0.000688	0.00516	CcSEcCtD
Etoricoxib—Haemoglobin—Temozolomide—malignant glioma	0.00068	0.0051	CcSEcCtD
Etoricoxib—Haemorrhage—Temozolomide—malignant glioma	0.000677	0.00507	CcSEcCtD
Etoricoxib—Hepatitis—Temozolomide—malignant glioma	0.000677	0.00507	CcSEcCtD
Etoricoxib—Visual impairment—Carmustine—malignant glioma	0.000675	0.00506	CcSEcCtD
Etoricoxib—Hypoaesthesia—Temozolomide—malignant glioma	0.000673	0.00505	CcSEcCtD
Etoricoxib—Hallucination—Temozolomide—malignant glioma	0.000673	0.00505	CcSEcCtD
Etoricoxib—Pharyngitis—Temozolomide—malignant glioma	0.000672	0.00503	CcSEcCtD
Etoricoxib—Urinary tract disorder—Temozolomide—malignant glioma	0.000668	0.00501	CcSEcCtD
Etoricoxib—Oedema peripheral—Temozolomide—malignant glioma	0.000667	0.005	CcSEcCtD
Etoricoxib—Connective tissue disorder—Temozolomide—malignant glioma	0.000665	0.00499	CcSEcCtD
Etoricoxib—Urethral disorder—Temozolomide—malignant glioma	0.000663	0.00497	CcSEcCtD
Etoricoxib—Eye disorder—Carmustine—malignant glioma	0.000654	0.00491	CcSEcCtD
Etoricoxib—Visual impairment—Temozolomide—malignant glioma	0.000652	0.00489	CcSEcCtD
Etoricoxib—Flushing—Carmustine—malignant glioma	0.00065	0.00487	CcSEcCtD
Etoricoxib—Erythema multiforme—Temozolomide—malignant glioma	0.00064	0.0048	CcSEcCtD
Etoricoxib—Eye disorder—Temozolomide—malignant glioma	0.000632	0.00474	CcSEcCtD
Etoricoxib—Tinnitus—Temozolomide—malignant glioma	0.000631	0.00473	CcSEcCtD
Etoricoxib—MAPK14—brain—malignant glioma	0.00063	0.0348	CbGeAlD
Etoricoxib—Cardiac disorder—Temozolomide—malignant glioma	0.000628	0.00471	CcSEcCtD
Etoricoxib—Flushing—Temozolomide—malignant glioma	0.000628	0.00471	CcSEcCtD
Etoricoxib—Arrhythmia—Carmustine—malignant glioma	0.000625	0.00469	CcSEcCtD
Etoricoxib—Alopecia—Carmustine—malignant glioma	0.000619	0.00464	CcSEcCtD
Etoricoxib—Angiopathy—Temozolomide—malignant glioma	0.000614	0.0046	CcSEcCtD
Etoricoxib—Mental disorder—Carmustine—malignant glioma	0.000613	0.0046	CcSEcCtD
Etoricoxib—Immune system disorder—Temozolomide—malignant glioma	0.000611	0.00458	CcSEcCtD
Etoricoxib—Mediastinal disorder—Temozolomide—malignant glioma	0.00061	0.00457	CcSEcCtD
Etoricoxib—Malnutrition—Carmustine—malignant glioma	0.000609	0.00457	CcSEcCtD
Etoricoxib—Erythema—Carmustine—malignant glioma	0.000609	0.00457	CcSEcCtD
Etoricoxib—Alopecia—Temozolomide—malignant glioma	0.000598	0.00448	CcSEcCtD
Etoricoxib—Mental disorder—Temozolomide—malignant glioma	0.000593	0.00444	CcSEcCtD
Etoricoxib—Malnutrition—Temozolomide—malignant glioma	0.000589	0.00442	CcSEcCtD
Etoricoxib—Erythema—Temozolomide—malignant glioma	0.000589	0.00442	CcSEcCtD
Etoricoxib—Dysgeusia—Temozolomide—malignant glioma	0.000577	0.00432	CcSEcCtD
Etoricoxib—Vision blurred—Carmustine—malignant glioma	0.000574	0.00431	CcSEcCtD
Etoricoxib—Tremor—Carmustine—malignant glioma	0.000571	0.00428	CcSEcCtD
Etoricoxib—Anaemia—Carmustine—malignant glioma	0.000563	0.00422	CcSEcCtD
Etoricoxib—Agitation—Carmustine—malignant glioma	0.00056	0.0042	CcSEcCtD
Etoricoxib—Vision blurred—Temozolomide—malignant glioma	0.000555	0.00416	CcSEcCtD
Etoricoxib—Tremor—Temozolomide—malignant glioma	0.000552	0.00414	CcSEcCtD
Etoricoxib—Anaemia—Temozolomide—malignant glioma	0.000544	0.00408	CcSEcCtD
Etoricoxib—Agitation—Temozolomide—malignant glioma	0.000541	0.00406	CcSEcCtD
Etoricoxib—Angioedema—Temozolomide—malignant glioma	0.000538	0.00404	CcSEcCtD
Etoricoxib—Celecoxib—PTGS2—malignant glioma	0.000534	0.0497	CrCbGaD
Etoricoxib—Hypertension—Carmustine—malignant glioma	0.000526	0.00395	CcSEcCtD
Etoricoxib—Palpitations—Temozolomide—malignant glioma	0.000521	0.0039	CcSEcCtD
Etoricoxib—Chest pain—Carmustine—malignant glioma	0.000519	0.00389	CcSEcCtD
Etoricoxib—Anxiety—Carmustine—malignant glioma	0.000517	0.00388	CcSEcCtD
Etoricoxib—Cough—Temozolomide—malignant glioma	0.000514	0.00385	CcSEcCtD
Etoricoxib—Hypertension—Temozolomide—malignant glioma	0.000509	0.00381	CcSEcCtD
Etoricoxib—Confusional state—Carmustine—malignant glioma	0.000502	0.00376	CcSEcCtD
Etoricoxib—Arthralgia—Temozolomide—malignant glioma	0.000501	0.00376	CcSEcCtD
Etoricoxib—Anxiety—Temozolomide—malignant glioma	0.0005	0.00375	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000498	0.00373	CcSEcCtD
Etoricoxib—Oedema—Carmustine—malignant glioma	0.000497	0.00373	CcSEcCtD
Etoricoxib—Infection—Carmustine—malignant glioma	0.000494	0.00371	CcSEcCtD
Etoricoxib—PTGS2—embryo—malignant glioma	0.000494	0.0272	CbGeAlD
Etoricoxib—Dry mouth—Temozolomide—malignant glioma	0.00049	0.00368	CcSEcCtD
Etoricoxib—Thrombocytopenia—Carmustine—malignant glioma	0.000487	0.00365	CcSEcCtD
Etoricoxib—Confusional state—Temozolomide—malignant glioma	0.000485	0.00363	CcSEcCtD
Etoricoxib—Oedema—Temozolomide—malignant glioma	0.000481	0.0036	CcSEcCtD
Etoricoxib—Anaphylactic shock—Temozolomide—malignant glioma	0.000481	0.0036	CcSEcCtD
Etoricoxib—Infection—Temozolomide—malignant glioma	0.000478	0.00358	CcSEcCtD
Etoricoxib—Anorexia—Carmustine—malignant glioma	0.000474	0.00355	CcSEcCtD
Etoricoxib—Nervous system disorder—Temozolomide—malignant glioma	0.000471	0.00353	CcSEcCtD
Etoricoxib—Thrombocytopenia—Temozolomide—malignant glioma	0.000471	0.00353	CcSEcCtD
Etoricoxib—Skin disorder—Temozolomide—malignant glioma	0.000467	0.0035	CcSEcCtD
Etoricoxib—Anorexia—Temozolomide—malignant glioma	0.000458	0.00344	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000453	0.0034	CcSEcCtD
Etoricoxib—Insomnia—Carmustine—malignant glioma	0.00045	0.00337	CcSEcCtD
Etoricoxib—Dyspnoea—Carmustine—malignant glioma	0.000443	0.00332	CcSEcCtD
Etoricoxib—Somnolence—Carmustine—malignant glioma	0.000442	0.00332	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000438	0.00328	CcSEcCtD
Etoricoxib—CYP2E1—telencephalon—malignant glioma	0.000436	0.0241	CbGeAlD
Etoricoxib—Insomnia—Temozolomide—malignant glioma	0.000435	0.00326	CcSEcCtD
Etoricoxib—Decreased appetite—Carmustine—malignant glioma	0.000432	0.00324	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Carmustine—malignant glioma	0.000429	0.00322	CcSEcCtD
Etoricoxib—Dyspnoea—Temozolomide—malignant glioma	0.000429	0.00321	CcSEcCtD
Etoricoxib—Somnolence—Temozolomide—malignant glioma	0.000427	0.0032	CcSEcCtD
Etoricoxib—Constipation—Carmustine—malignant glioma	0.000425	0.00319	CcSEcCtD
Etoricoxib—Pain—Carmustine—malignant glioma	0.000425	0.00319	CcSEcCtD
Etoricoxib—Dyspepsia—Temozolomide—malignant glioma	0.000423	0.00317	CcSEcCtD
Etoricoxib—Decreased appetite—Temozolomide—malignant glioma	0.000418	0.00313	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000415	0.00311	CcSEcCtD
Etoricoxib—Fatigue—Temozolomide—malignant glioma	0.000414	0.00311	CcSEcCtD
Etoricoxib—Pain—Temozolomide—malignant glioma	0.000411	0.00308	CcSEcCtD
Etoricoxib—Constipation—Temozolomide—malignant glioma	0.000411	0.00308	CcSEcCtD
Etoricoxib—Feeling abnormal—Carmustine—malignant glioma	0.00041	0.00307	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Carmustine—malignant glioma	0.000407	0.00305	CcSEcCtD
Etoricoxib—PTGS2—telencephalon—malignant glioma	0.000401	0.0221	CbGeAlD
Etoricoxib—Feeling abnormal—Temozolomide—malignant glioma	0.000396	0.00297	CcSEcCtD
Etoricoxib—Abdominal pain—Carmustine—malignant glioma	0.000393	0.00295	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Temozolomide—malignant glioma	0.000393	0.00295	CcSEcCtD
Etoricoxib—CYP2D6—brainstem—malignant glioma	0.000389	0.0215	CbGeAlD
Etoricoxib—Urticaria—Temozolomide—malignant glioma	0.000382	0.00286	CcSEcCtD
Etoricoxib—Abdominal pain—Temozolomide—malignant glioma	0.00038	0.00285	CcSEcCtD
Etoricoxib—Hypersensitivity—Carmustine—malignant glioma	0.000366	0.00275	CcSEcCtD
Etoricoxib—Asthenia—Carmustine—malignant glioma	0.000357	0.00268	CcSEcCtD
Etoricoxib—Hypersensitivity—Temozolomide—malignant glioma	0.000354	0.00266	CcSEcCtD
Etoricoxib—CYP2D6—telencephalon—malignant glioma	0.000345	0.019	CbGeAlD
Etoricoxib—Asthenia—Temozolomide—malignant glioma	0.000345	0.00259	CcSEcCtD
Etoricoxib—CYP2E1—medulla oblongata—malignant glioma	0.000343	0.0189	CbGeAlD
Etoricoxib—Diarrhoea—Carmustine—malignant glioma	0.00034	0.00255	CcSEcCtD
Etoricoxib—Pruritus—Temozolomide—malignant glioma	0.00034	0.00255	CcSEcCtD
Etoricoxib—Dizziness—Carmustine—malignant glioma	0.000329	0.00247	CcSEcCtD
Etoricoxib—Diarrhoea—Temozolomide—malignant glioma	0.000329	0.00247	CcSEcCtD
Etoricoxib—Dizziness—Temozolomide—malignant glioma	0.000318	0.00238	CcSEcCtD
Etoricoxib—Vomiting—Carmustine—malignant glioma	0.000316	0.00237	CcSEcCtD
Etoricoxib—PTGS2—medulla oblongata—malignant glioma	0.000315	0.0174	CbGeAlD
Etoricoxib—Rash—Carmustine—malignant glioma	0.000314	0.00235	CcSEcCtD
Etoricoxib—Dermatitis—Carmustine—malignant glioma	0.000313	0.00235	CcSEcCtD
Etoricoxib—Headache—Carmustine—malignant glioma	0.000312	0.00234	CcSEcCtD
Etoricoxib—Vomiting—Temozolomide—malignant glioma	0.000306	0.00229	CcSEcCtD
Etoricoxib—CYP2E1—spinal cord—malignant glioma	0.000305	0.0169	CbGeAlD
Etoricoxib—Rash—Temozolomide—malignant glioma	0.000303	0.00227	CcSEcCtD
Etoricoxib—Dermatitis—Temozolomide—malignant glioma	0.000303	0.00227	CcSEcCtD
Etoricoxib—Headache—Temozolomide—malignant glioma	0.000301	0.00226	CcSEcCtD
Etoricoxib—Nausea—Carmustine—malignant glioma	0.000295	0.00222	CcSEcCtD
Etoricoxib—PTGS2—midbrain—malignant glioma	0.000288	0.0159	CbGeAlD
Etoricoxib—Nausea—Temozolomide—malignant glioma	0.000286	0.00214	CcSEcCtD
Etoricoxib—PTGS2—spinal cord—malignant glioma	0.000281	0.0155	CbGeAlD
Etoricoxib—CYP2E1—central nervous system—malignant glioma	0.000248	0.0137	CbGeAlD
Etoricoxib—CYP2E1—cerebellum—malignant glioma	0.000242	0.0134	CbGeAlD
Etoricoxib—PTGS2—central nervous system—malignant glioma	0.000228	0.0126	CbGeAlD
Etoricoxib—PTGS2—cerebellum—malignant glioma	0.000223	0.0123	CbGeAlD
Etoricoxib—CYP3A4—central nervous system—malignant glioma	0.000199	0.011	CbGeAlD
Etoricoxib—CYP2E1—brain—malignant glioma	0.000197	0.0109	CbGeAlD
Etoricoxib—CYP2D6—central nervous system—malignant glioma	0.000196	0.0108	CbGeAlD
Etoricoxib—CYP2D6—cerebellum—malignant glioma	0.000192	0.0106	CbGeAlD
Etoricoxib—PTGS2—brain—malignant glioma	0.000181	0.00999	CbGeAlD
Etoricoxib—CYP2D6—brain—malignant glioma	0.000156	0.00859	CbGeAlD
Etoricoxib—CYP3A4—Metabolism—ASMT—malignant glioma	1.89e-05	9.68e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—IDH1—malignant glioma	1.88e-05	9.64e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—BCHE—malignant glioma	1.88e-05	9.64e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—IDH1—malignant glioma	1.86e-05	9.56e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—SLC5A5—malignant glioma	1.86e-05	9.52e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—IDH2—malignant glioma	1.85e-05	9.5e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PTK2—malignant glioma	1.84e-05	9.45e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—PIK3CA—malignant glioma	1.84e-05	9.44e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.83e-05	9.37e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—SPHK1—malignant glioma	1.82e-05	9.33e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PIK3CD—malignant glioma	1.82e-05	9.32e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—HES1—malignant glioma	1.81e-05	9.28e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—KRAS—malignant glioma	1.8e-05	9.25e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—SPHK1—malignant glioma	1.8e-05	9.25e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NCOR1—malignant glioma	1.8e-05	9.23e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYP2C18—malignant glioma	1.78e-05	9.14e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—TP53—malignant glioma	1.78e-05	9.13e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—BCAN—malignant glioma	1.77e-05	9.1e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—BCHE—malignant glioma	1.77e-05	9.08e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYP2C18—malignant glioma	1.77e-05	9.06e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.75e-05	9.01e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—SLC5A5—malignant glioma	1.75e-05	8.97e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	1.75e-05	8.96e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP2B6—malignant glioma	1.74e-05	8.93e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—FGF2—malignant glioma	1.74e-05	8.92e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CDKN2B—malignant glioma	1.73e-05	8.88e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PDGFRA—malignant glioma	1.72e-05	8.84e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SPP1—malignant glioma	1.67e-05	8.58e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.67e-05	8.55e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.66e-05	8.54e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—PIK3CA—malignant glioma	1.66e-05	8.5e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—BCL2—malignant glioma	1.65e-05	8.47e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HES1—malignant glioma	1.65e-05	8.47e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NCOR1—malignant glioma	1.64e-05	8.42e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IFNG—malignant glioma	1.64e-05	8.39e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MDM2—malignant glioma	1.63e-05	8.35e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—RAF1—malignant glioma	1.62e-05	8.32e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.61e-05	8.24e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—ERBB2—malignant glioma	1.6e-05	8.23e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—IDH1—malignant glioma	1.59e-05	8.17e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TERT—malignant glioma	1.58e-05	8.13e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PIK3CB—malignant glioma	1.58e-05	8.12e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PDGFRA—malignant glioma	1.57e-05	8.06e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GSTT1—malignant glioma	1.57e-05	8.04e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PDGFB—malignant glioma	1.55e-05	7.94e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—SPHK1—malignant glioma	1.54e-05	7.91e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FGFR1—malignant glioma	1.54e-05	7.9e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—AKT1—malignant glioma	1.53e-05	7.86e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.52e-05	7.78e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.52e-05	7.78e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—HIF1A—malignant glioma	1.52e-05	7.78e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP2C18—malignant glioma	1.51e-05	7.75e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—AKT1—malignant glioma	1.5e-05	7.71e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GSTP1—malignant glioma	1.49e-05	7.67e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTGS1—malignant glioma	1.47e-05	7.53e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CAV1—malignant glioma	1.47e-05	7.52e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.46e-05	7.51e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.46e-05	7.51e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL1B—malignant glioma	1.46e-05	7.49e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CAT—malignant glioma	1.45e-05	7.47e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL2—malignant glioma	1.45e-05	7.46e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KDR—malignant glioma	1.45e-05	7.44e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HLA-A—malignant glioma	1.45e-05	7.42e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TERT—malignant glioma	1.45e-05	7.42e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GSTT1—malignant glioma	1.44e-05	7.39e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—IDH2—malignant glioma	1.43e-05	7.33e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GSTT1—malignant glioma	1.43e-05	7.33e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.42e-05	7.3e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PDGFB—malignant glioma	1.41e-05	7.24e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GSTP1—malignant glioma	1.41e-05	7.22e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—FGFR1—malignant glioma	1.4e-05	7.2e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—F2—malignant glioma	1.4e-05	7.16e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FN1—malignant glioma	1.4e-05	7.16e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HIF1A—malignant glioma	1.38e-05	7.1e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—BAD—malignant glioma	1.38e-05	7.08e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—NCOR1—malignant glioma	1.37e-05	7.05e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CAT—malignant glioma	1.37e-05	7.03e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PTEN—malignant glioma	1.37e-05	7.02e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NOTCH1—malignant glioma	1.37e-05	7.01e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—BCHE—malignant glioma	1.36e-05	7e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—AKT1—malignant glioma	1.35e-05	6.94e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTGS1—malignant glioma	1.35e-05	6.93e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—SLC5A5—malignant glioma	1.35e-05	6.92e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP2B6—malignant glioma	1.34e-05	6.89e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTGS1—malignant glioma	1.34e-05	6.87e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CD80—malignant glioma	1.34e-05	6.86e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CAV1—malignant glioma	1.34e-05	6.86e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—APC—malignant glioma	1.34e-05	6.85e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CG—malignant glioma	1.34e-05	6.85e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.33e-05	6.84e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EGF—malignant glioma	1.32e-05	6.77e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PTPN11—malignant glioma	1.31e-05	6.73e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.3e-05	6.65e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—NCOR1—malignant glioma	1.29e-05	6.64e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.27e-05	6.54e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	1.26e-05	6.48e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—BAD—malignant glioma	1.26e-05	6.45e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—BCHE—malignant glioma	1.25e-05	6.44e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—BRAF—malignant glioma	1.25e-05	6.44e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.25e-05	6.42e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NOTCH1—malignant glioma	1.25e-05	6.39e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—BCHE—malignant glioma	1.24e-05	6.39e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—SLC5A5—malignant glioma	1.24e-05	6.36e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—SLC5A5—malignant glioma	1.23e-05	6.31e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—IDH1—malignant glioma	1.23e-05	6.31e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—STAT3—malignant glioma	1.22e-05	6.28e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AKT2—malignant glioma	1.22e-05	6.27e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTT1—malignant glioma	1.22e-05	6.26e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CD80—malignant glioma	1.22e-05	6.26e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—APC—malignant glioma	1.22e-05	6.25e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EGF—malignant glioma	1.2e-05	6.18e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PTPN11—malignant glioma	1.2e-05	6.14e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SPHK1—malignant glioma	1.19e-05	6.1e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CD—malignant glioma	1.17e-05	6.02e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP2C18—malignant glioma	1.16e-05	5.98e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.16e-05	5.97e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	1.15e-05	5.91e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—BRAF—malignant glioma	1.14e-05	5.88e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTGS1—malignant glioma	1.14e-05	5.87e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.14e-05	5.85e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MYC—malignant glioma	1.13e-05	5.8e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FGF2—malignant glioma	1.12e-05	5.77e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CAV1—malignant glioma	1.12e-05	5.75e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—AKT2—malignant glioma	1.11e-05	5.72e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—EGFR—malignant glioma	1.11e-05	5.7e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.1e-05	5.65e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GSTP1—malignant glioma	1.09e-05	5.57e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CD—malignant glioma	1.07e-05	5.5e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.07e-05	5.49e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—BCHE—malignant glioma	1.06e-05	5.46e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CAT—malignant glioma	1.06e-05	5.42e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CAV1—malignant glioma	1.05e-05	5.41e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MDM2—malignant glioma	1.05e-05	5.4e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—SLC5A5—malignant glioma	1.05e-05	5.39e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—KRAS—malignant glioma	1.05e-05	5.39e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—RAF1—malignant glioma	1.05e-05	5.38e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ERBB2—malignant glioma	1.04e-05	5.32e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—FGF2—malignant glioma	1.03e-05	5.26e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CB—malignant glioma	1.02e-05	5.25e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CG—malignant glioma	1.02e-05	5.24e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1e-05	5.15e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GSTP1—malignant glioma	9.99e-06	5.13e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—NCOR1—malignant glioma	9.98e-06	5.12e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	9.93e-06	5.1e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GSTP1—malignant glioma	9.9e-06	5.08e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PPARG—malignant glioma	9.84e-06	5.05e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	9.84e-06	5.05e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CXCL8—malignant glioma	9.83e-06	5.05e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CAT—malignant glioma	9.72e-06	4.99e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PIK3CA—malignant glioma	9.65e-06	4.95e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CAT—malignant glioma	9.63e-06	4.94e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CG—malignant glioma	9.6e-06	4.93e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MDM2—malignant glioma	9.59e-06	4.92e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—RAF1—malignant glioma	9.56e-06	4.91e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—ERBB2—malignant glioma	9.46e-06	4.85e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTT1—malignant glioma	9.42e-06	4.83e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CASP3—malignant glioma	9.41e-06	4.83e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL2—malignant glioma	9.39e-06	4.82e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CB—malignant glioma	9.33e-06	4.79e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PPARG—malignant glioma	9.27e-06	4.76e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—NCOR1—malignant glioma	9.18e-06	4.71e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—NCOR1—malignant glioma	9.1e-06	4.67e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CD—malignant glioma	8.97e-06	4.6e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MMP9—malignant glioma	8.89e-06	4.56e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PTEN—malignant glioma	8.84e-06	4.54e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTGS1—malignant glioma	8.83e-06	4.53e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	8.58e-06	4.4e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTP1—malignant glioma	8.46e-06	4.34e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CD—malignant glioma	8.44e-06	4.33e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CAT—malignant glioma	8.23e-06	4.22e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—BCHE—malignant glioma	8.21e-06	4.21e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CAV1—malignant glioma	8.13e-06	4.17e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SLC5A5—malignant glioma	8.1e-06	4.16e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PTEN—malignant glioma	8.06e-06	4.14e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—VEGFA—malignant glioma	7.98e-06	4.1e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—STAT3—malignant glioma	7.91e-06	4.06e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—AKT1—malignant glioma	7.88e-06	4.04e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—AKT1—malignant glioma	7.84e-06	4.02e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CB—malignant glioma	7.82e-06	4.01e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NCOR1—malignant glioma	7.77e-06	3.99e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	7.77e-06	3.99e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CAV1—malignant glioma	7.48e-06	3.84e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CAV1—malignant glioma	7.42e-06	3.81e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CG—malignant glioma	7.41e-06	3.8e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CB—malignant glioma	7.36e-06	3.78e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MYC—malignant glioma	7.35e-06	3.77e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTGS2—malignant glioma	7.29e-06	3.74e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—STAT3—malignant glioma	7.21e-06	3.7e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EGFR—malignant glioma	7.19e-06	3.69e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PPARG—malignant glioma	7.15e-06	3.67e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	7.08e-06	3.64e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CG—malignant glioma	6.81e-06	3.5e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KRAS—malignant glioma	6.79e-06	3.48e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CG—malignant glioma	6.75e-06	3.47e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PTEN—malignant glioma	6.75e-06	3.47e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MYC—malignant glioma	6.7e-06	3.44e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PPARG—malignant glioma	6.58e-06	3.38e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EGFR—malignant glioma	6.55e-06	3.36e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTP1—malignant glioma	6.53e-06	3.35e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PPARG—malignant glioma	6.52e-06	3.35e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CD—malignant glioma	6.51e-06	3.34e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTEN—malignant glioma	6.36e-06	3.26e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CAT—malignant glioma	6.35e-06	3.26e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CAV1—malignant glioma	6.34e-06	3.25e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CA—malignant glioma	6.24e-06	3.2e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—KRAS—malignant glioma	6.19e-06	3.18e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.05e-06	3.11e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TP53—malignant glioma	6.03e-06	3.1e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NCOR1—malignant glioma	6e-06	3.08e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CD—malignant glioma	5.99e-06	3.07e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CD—malignant glioma	5.94e-06	3.05e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CG—malignant glioma	5.77e-06	2.96e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CA—malignant glioma	5.69e-06	2.92e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CB—malignant glioma	5.68e-06	2.91e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTGS2—malignant glioma	5.62e-06	2.89e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PPARG—malignant glioma	5.57e-06	2.86e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CB—malignant glioma	5.22e-06	2.68e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CB—malignant glioma	5.18e-06	2.66e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTGS2—malignant glioma	5.17e-06	2.66e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTGS2—malignant glioma	5.13e-06	2.63e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AKT1—malignant glioma	5.09e-06	2.61e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CD—malignant glioma	5.07e-06	2.6e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTEN—malignant glioma	4.91e-06	2.52e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CAV1—malignant glioma	4.89e-06	2.51e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CA—malignant glioma	4.76e-06	2.45e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—AKT1—malignant glioma	4.65e-06	2.39e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTEN—malignant glioma	4.51e-06	2.32e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CA—malignant glioma	4.49e-06	2.3e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTEN—malignant glioma	4.47e-06	2.3e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CG—malignant glioma	4.45e-06	2.29e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CB—malignant glioma	4.42e-06	2.27e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTGS2—malignant glioma	4.38e-06	2.25e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PPARG—malignant glioma	4.3e-06	2.21e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CD—malignant glioma	3.92e-06	2.01e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—AKT1—malignant glioma	3.89e-06	2e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTEN—malignant glioma	3.82e-06	1.96e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—AKT1—malignant glioma	3.66e-06	1.88e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CA—malignant glioma	3.46e-06	1.78e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CB—malignant glioma	3.41e-06	1.75e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTGS2—malignant glioma	3.38e-06	1.74e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CA—malignant glioma	3.18e-06	1.63e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CA—malignant glioma	3.16e-06	1.62e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTEN—malignant glioma	2.95e-06	1.51e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—AKT1—malignant glioma	2.83e-06	1.45e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CA—malignant glioma	2.7e-06	1.38e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—AKT1—malignant glioma	2.6e-06	1.33e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—AKT1—malignant glioma	2.58e-06	1.32e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—AKT1—malignant glioma	2.2e-06	1.13e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CA—malignant glioma	2.08e-06	1.07e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—AKT1—malignant glioma	1.7e-06	8.72e-06	CbGpPWpGaD
